Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials.

Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials.

Two once-daily inhaled bronchodilators, indacaterol and tiotropium, are widely used as first-line therapy in stable COPD patients. This study was performed to compare the clinical efficacy and safety between indacaterol and tiotropium in patients with moderate-to-severe COPD. MEDLINE, EMBASE, and Co...

Full description

Bibliographic Details
Main Authors:	Jung Soo Kim, Jinkyeong Park, Seong Yong Lim, Yeon-Mok Oh, Kwang Ha Yoo, Yong Bum Park, Seung Soo Sheen, Min-Ji Kim, K C Carriere, Ji Ye Jung, Hye Yun Park
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4370711?pdf=render

Similar Items

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
by: Sang Haak Lee, et al.
Published: (2021-04-01)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
by: Anzueto AR, et al.
Published: (2017-05-01)

Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study
by: Danilo Cortozi Berton, et al.

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
by: Antonio Molino, et al.
Published: (2017-09-01)

Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study
by: Fujimoto K, et al.
Published: (2017-11-01)

Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium tiotropium: the RED trial
by: Jessie Beaulieu, et al.
Published: (2020-07-01)

Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study
by: Kaplan A, et al.
Published: (2019-01-01)

An update on the use of indacaterol in patients with COPD
by: Nadia S. Brienza, et al.
Published: (2011-02-01)

High urinary desmosine is associated with long-term mortality in patients with COPD
by: Changhwan Kim, et al.
Published: (2023-06-01)

Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA versus ICS/LABA in COPD Management: Findings from Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study
by: Ye Jin Lee, et al.
Published: (2021-12-01)

Tiotropium - Advancing the treatment of COPD
by: Chambers, S, et al.
Published: (2008)

Tiotropium as essential maintenance therapy in COPD
by: M. Decramer
Published: (2006-12-01)

Efficacy of tiotropium in the prevention of exacerbations of COPD
by: Antonio Anzueto, et al.
Published: (2009-06-01)

Cancer development in patients with COPD: a retrospective analysis of the National Health Insurance Service-National Sample Cohort in Korea
by: Song Vogue Ahn, et al.
Published: (2020-06-01)

Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease
by: Inui N, et al.
Published: (2015-06-01)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
by: Ichinose M, et al.
Published: (2018-07-01)

Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort
by: Hye Yun Park, et al.
Published: (2018-03-01)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
by: Vincken W, et al.
Published: (2014-02-01)

Tiotropium in COPD: clinical outcomes and economic evidence
by: Orietta Zaniolo, et al.
Published: (2010-03-01)

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
by: Lan Y, et al.
Published: (2023-09-01)

Reliability of Portable Spirometry Performed in the Korea National Health and Nutrition Examination Survey Compared to Conventional Spirometry
by: Hye Jung Park, et al.
Published: (2021-10-01)

Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
by: Shamim Ahmed, et al.
Published: (2022-02-01)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
by: Beatrix Balint, et al.
Published: (2010-09-01)

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
by: Dave Singh, et al.
Published: (2022-02-01)

Preparation and Evaluation of Mucus-Penetrating Inhalable Microparticles of Tiotropium Bromide Containing Sodium Glycocholate
by: Yong-Bin Kwon, et al.
Published: (2022-07-01)

Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts
by: Se Hee Lee, et al.
Published: (2019-03-01)

Effect of add-on therapy of tiotropium in COPD treated with theophylline
by: Tomotaka Kawayama, et al.
Published: (2008-03-01)

Socioeconomic gradients in tiotropium use among adults with COPD
by: Paul D Blanc, et al.
Published: (2008-10-01)

Safety, tolerability and risk benefit analysis of tiotropium in COPD
by: Yuji Oba, et al.
Published: (2008-11-01)

Sarcopenia is associated with cardiovascular risk in men with COPD, independent of adiposity
by: Ah Young Leem, et al.
Published: (2022-07-01)

FVC, but not FEV1, is associated with clinical outcomes of asthma-COPD overlap
by: Tai Joon An, et al.
Published: (2022-08-01)

A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
by: Juvelekian G, et al.
Published: (2015-10-01)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
by: Horita N, et al.
Published: (2015-04-01)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
by: Ridolo E, et al.
Published: (2019-01-01)

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
by: Koehorst-ter Huurne K, et al.
Published: (2016-07-01)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
by: Pelaia G, et al.
Published: (2015-10-01)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
by: Derom E, et al.
Published: (2016-12-01)

Definitions of Chronic Obstructive Pulmonary Disease and Chronic Obstructive Pulmonary Disease Exacerbation: A Modified Delphi Survey
by: Yong Bum Park, et al.
Published: (2023-07-01)

Air Trapping and the Risk of COPD Exacerbation: Analysis From Prospective KOCOSS Cohort
by: Youlim Kim, et al.
Published: (2022-03-01)

Effect of Broncho-Vaxom (OM-85) on the frequency of chronic obstructive pulmonary disease (COPD) exacerbations
by: Joon Young Choi, et al.
Published: (2023-10-01)